AA
ALPS Advisors Portfolio holdings
AUM
$17.3B
1-Year Return
13.43%
This Quarter Return
+11.67%
1 Year Return
+13.43%
3 Year Return
+69.62%
5 Year Return
+161.48%
10 Year Return
+94.79%
AUM
$9.22B
AUM Growth
+$331M
(+3.7%)
Cap. Flow
-$367M
Cap. Flow
% of AUM
-3.98%
Top 10 Holdings %
Top 10 Hldgs %
56.36%
Holding
1,043
New
155
Increased
182
Reduced
486
Closed
210
Top Buys
| 1 |
Hess Midstream
HESM
|
+$148M |
| 2 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$106M |
| 3 |
CEQP
Crestwood Equity Partners LP
CEQP
|
+$99.9M |
| 4 |
MPLX
MPLX
|
+$76.6M |
| 5 |
Energy Transfer Partners
ET
|
+$70.9M |
Top Sells
| 1 |
Western Midstream Partners
WES
|
+$541M |
| 2 |
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
|
+$338M |
| 3 |
Williams Companies
WMB
|
+$39.2M |
| 4 |
Exxon Mobil
XOM
|
+$31.4M |
| 5 |
Verizon
VZ
|
+$24.2M |
Sector Composition
| 1 | Energy | 65.72% |
| 2 | Technology | 5.09% |
| 3 | Consumer Discretionary | 3.8% |
| 4 | Healthcare | 3.45% |
| 5 | Industrials | 3.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
WBA
801
DELISTED
Walgreens Boots Alliance
WBA
| $207K | ﹤0.01% |
4,617
-470,985
| -99% | -$21.1M |
|
802
Service Corp International
SCI
$11.1B
| $202K | ﹤0.01% |
3,065
-6,924
| -69% | -$456K |
|
803
Ford
F
$45.9B
| $199K | ﹤0.01% |
11,791
-3,663
| -24% | -$61.8K |
|
804
O-I Glass
OI
$1.98B
| $199K | ﹤0.01% |
15,076
-4,689
| -24% | -$61.9K |
|
|
AVEO
805
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $197K | ﹤0.01% |
35,325
-4,450
| -11% | -$24.8K |
|
806
BioAtla
BCAB
$37.8M
| $191K | ﹤0.01% |
38,193
-4,438
| -10% | -$22.2K |
|
|
EFTR
807
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| $187K | ﹤0.01% |
1,861
-217
| -10% | -$21.8K |
|
808
PDS Biotechnology
PDSB
$54.1M
| $181K | ﹤0.01% |
29,221
-3,685
| -11% | -$22.8K |
|
809
CytomX Therapeutics
CTMX
$340M
| $179K | ﹤0.01% |
67,211
-8,302
| -11% | -$22.1K |
|
810
Dianthus Therapeutics
DNTH
$1.09B
| $175K | ﹤0.01% |
3,777
-474
| -11% | -$22K |
|
811
SunCoke Energy
SXC
$645M
| $171K | ﹤0.01% |
19,195
-5,967
| -24% | -$53.2K |
|
812
SAB Biotherapeutics
SABS
$22.7M
| $170K | ﹤0.01% |
4,508
-523
| -10% | -$19.7K |
|
813
NGL Energy Partners
NGL
$761M
| $164K | ﹤0.01% |
73,724
+12,334
| +20% | +$27.4K |
|
814
Atossa Therapeutics
ATOS
$105M
| $163K | ﹤0.01% |
130,141
-16,401
| -11% | -$20.5K |
|
815
INmune Bio
INMB
$47.6M
| $155K | ﹤0.01% |
18,363
-2,287
| -11% | -$19.3K |
|
|
CKPT
816
DELISTED
Checkpoint Therapeutics
CKPT
| $152K | ﹤0.01% |
8,609
-1,085
| -11% | -$19.2K |
|
|
IMPL
817
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $151K | ﹤0.01% |
23,675
-2,987
| -11% | -$19.1K |
|
818
Archrock
AROC
$4.27B
| $148K | ﹤0.01% |
16,088
-5,004
| -24% | -$46K |
|
|
SURF
819
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $142K | ﹤0.01% |
48,267
-5,121
| -10% | -$15.1K |
|
820
Fortress Biotech
FBIO
$101M
| $139K | ﹤0.01% |
6,827
-859
| -11% | -$17.5K |
|
821
CoreCivic
CXW
$2.14B
| $126K | ﹤0.01% |
11,248
-3,492
| -24% | -$39.1K |
|
822
Spyre Therapeutics
SYRE
$994M
| $117K | ﹤0.01% |
2,029
-254
| -11% | -$14.6K |
|
823
Tonix Pharmaceuticals
TNXP
$215M
| $117K | ﹤0.01% |
1
| – | – |
|
824
Acco Brands
ACCO
$363M
| $115K | ﹤0.01% |
14,354
-4,464
| -24% | -$35.8K |
|
825
Cardiff Oncology
CRDF
$144M
| $110K | ﹤0.01% |
44,511
-4,048
| -8% | -$10K |
|